CO6470875A2 - Un compuesto para usar en la prevención y tratamiento de enfermedades cardiovasculares - Google Patents

Un compuesto para usar en la prevención y tratamiento de enfermedades cardiovasculares

Info

Publication number
CO6470875A2
CO6470875A2 CO11169701A CO11169701A CO6470875A2 CO 6470875 A2 CO6470875 A2 CO 6470875A2 CO 11169701 A CO11169701 A CO 11169701A CO 11169701 A CO11169701 A CO 11169701A CO 6470875 A2 CO6470875 A2 CO 6470875A2
Authority
CO
Colombia
Prior art keywords
compound
prevention
treatment
cardiovascular diseases
composite
Prior art date
Application number
CO11169701A
Other languages
English (en)
Inventor
Che Idris Hjh Che Anishas Hj
Nagendran Balasundram
Ravigadevi Sambanthamurthi
Yew Ai Tan
Manickam Kalyana Sundram P
Mohd Basri Wahid
Original Assignee
Malaysian Palm Oil Board
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Malaysian Palm Oil Board filed Critical Malaysian Palm Oil Board
Publication of CO6470875A2 publication Critical patent/CO6470875A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/889—Arecaceae, Palmae or Palmaceae (Palm family), e.g. date or coconut palm or palmetto
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Un compuesto para usar en la preparación de un medicamento para la prevención y tratamiento de enfermedades cardiovasculares, dicho compuestos incluye los efluentes de molienda de la palma aceitera.Se suministra un compuesto para usar en la prevención de enfermedades cardiovasculares, dicho compuesto además incluye Vitamina E.Además, se relaciona al uso de una cantidad efectiva terapéuticamente de un compuesto con o sin vitamina E, en la preparación de un medicamento que previene o inhibe la enfermedad cardiovascular en un individuo al administrarla en un individuo con necesidad de tratamiento.
CO11169701A 2009-05-18 2011-12-09 Un compuesto para usar en la prevención y tratamiento de enfermedades cardiovasculares CO6470875A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MYPI20092024A MY161839A (en) 2009-05-18 2009-05-18 A composition for use in the prevention and treatment of cardiovascular diseases

Publications (1)

Publication Number Publication Date
CO6470875A2 true CO6470875A2 (es) 2012-06-29

Family

ID=43126341

Family Applications (1)

Application Number Title Priority Date Filing Date
CO11169701A CO6470875A2 (es) 2009-05-18 2011-12-09 Un compuesto para usar en la prevención y tratamiento de enfermedades cardiovasculares

Country Status (7)

Country Link
US (3) US8778419B2 (es)
EP (1) EP2432486B1 (es)
CN (1) CN102573869B (es)
BR (1) BRPI1015468A2 (es)
CO (1) CO6470875A2 (es)
MY (1) MY161839A (es)
WO (1) WO2010134799A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY161839A (en) 2009-05-18 2017-05-15 Malaysian Palm Oil Board A composition for use in the prevention and treatment of cardiovascular diseases
MY173655A (en) * 2009-06-09 2020-02-14 Malaysian Palm Oil Board Composition and method for improving vascular health
MY185582A (en) 2010-01-07 2021-05-24 Malaysian Palm Oil Board Anti-obesity and anti-dyslipidemic effects of oil palm phenolics in preventing atheroslerosis and cardiovascular disease
US10178869B2 (en) * 2011-02-11 2019-01-15 Roberto Crea Treatment of Elaeis fruit products with antioxidants
CN109394932A (zh) * 2018-10-09 2019-03-01 昆明理工大学 棕榈果不同状态多酚提取物的制备方法及应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6054128A (en) * 1997-09-29 2000-04-25 Wakat; Diane Dietary supplements for the cardiovascular system
MY134878A (en) * 1998-09-24 2007-12-31 Palm Oil Res And Dev Board Treatment of liquors derived from oil-bearing fruit.
US7887852B2 (en) * 2005-06-03 2011-02-15 Soft Gel Technologies, Inc. Soft gel capsules containing polymethoxylated flavones and palm oil tocotrienols
US20050249803A1 (en) 2005-06-03 2005-11-10 Udell Ronald G Soft gel capsules containing polymethoxylated flavones and palm oil tocotrienols
WO2007131106A2 (en) 2006-05-03 2007-11-15 Silver Palate Kitchens, Inc. Astringency-compensated polyphenolic antioxidant-containing comestible composition
WO2008090460A1 (en) 2007-01-26 2008-07-31 Probelte Pharma, S.A. Process and apparatus for the production of hydroxytyrosol containing extract from olives and solids containing residues of olive oil extraction
MY169539A (en) * 2007-04-12 2019-04-22 Malaysian Palm Oil Board Palm phenolics and flavonoids as potent biological and chemical antioxidants for applications in foods and edible oils
ES2362576T3 (es) 2007-07-23 2011-07-07 Probelte Pharma, S.A. Aceites enriquecidos con hidroxitirosol y sus usos.
MY184667A (en) * 2007-07-23 2021-04-15 Malaysian Palm Oil Board An antiviral composition
MY157650A (en) * 2008-03-06 2016-07-15 Nova Lab Sdn Bhd Extract from oil palm leaves comprising phenolic acids
US8071143B2 (en) * 2008-04-02 2011-12-06 Brandeis University Methods for the treatment or prevention of diabetes mellitus and other metabolic imbalances
MY161839A (en) 2009-05-18 2017-05-15 Malaysian Palm Oil Board A composition for use in the prevention and treatment of cardiovascular diseases
MY185582A (en) * 2010-01-07 2021-05-24 Malaysian Palm Oil Board Anti-obesity and anti-dyslipidemic effects of oil palm phenolics in preventing atheroslerosis and cardiovascular disease

Also Published As

Publication number Publication date
US20120121732A1 (en) 2012-05-17
US20140342023A1 (en) 2014-11-20
US20150224162A1 (en) 2015-08-13
EP2432486B1 (en) 2018-05-09
EP2432486A1 (en) 2012-03-28
US8778419B2 (en) 2014-07-15
CN102573869B (zh) 2015-04-08
MY161839A (en) 2017-05-15
WO2010134799A1 (en) 2010-11-25
CN102573869A (zh) 2012-07-11
US9839662B2 (en) 2017-12-12
BRPI1015468A2 (pt) 2019-07-16
EP2432486A4 (en) 2013-02-13

Similar Documents

Publication Publication Date Title
ECSP088874A (es) Uso de flibanserina para el tratamiento de trastornos posmenopausicos del deseo sexual
ECSP088504A (es) Uso de flibanserina para el tratamiento de trastornos del deseo sexual premenopáusicos
PA8849701A1 (es) Forma de dosificacion farmaceutica que comprende nifedipino o nisoldipino y un antagonista de anglotensina ii y/o un diuretico
GT200800250A (es) Arilimidazolonas y ariltriazolonas sustituidas como inhibidores de receptores de vasopresina
CL2013001136A1 (es) Un agente inhibitorio de la fosfodiesterasa 7 (pde7) para ser usado en el tratamiento o la reduccion de la posibilidad de una adiccion; y composicion farmaceutica, forma de dosificacion unitaria y kit farmaceutico que incluyen al inhibidor de fosfodiesterasa 7 (pde7) y un agente terapeutico adicional.
CL2011001529A1 (es) Uso de un modulador o agonista de los receptores s1p derivado de 2-amino-propan-1,3-diol o 2-amino-propanol para tratar una enfermedad cronica larga en un sujeto, de manera de conseguir una disminucion diaria en la frecuencia cardiaca de 2 latidos/minutos o menos; y kit que lo comprende.
CL2012001950A1 (es) Uso de una cepa bacteriana probiotico en la fabricacion de un medicamento o composicion nutricional en humanos o animales para alterar los patrones del sueño
CL2008003901A1 (es) Uso de un inhibidor de hedgehog para extender la sobrevida libre de recidiva en un paciente con cancer, que se encuentra en quimioterapia o ha sido tratado previamente con quimioterapia.
CO6470875A2 (es) Un compuesto para usar en la prevención y tratamiento de enfermedades cardiovasculares
NI200800176A (es) Uso de derivados de sulfamidas heterocíclicas benzo-fusionadas para el tratamiento de la depresión
CL2011002548A1 (es) Compuestos derivados de resolviina; composicion farmaceutica; uso de la composicion; kit farmaceutico; combinacion farmaceutica; uso de los compuestos en el tratamiento y/o prevencion de una condicion oftalmica.
ES2552654T3 (es) Uso de LCAT para tratar la anemia y la disfunción de los glóbulos rojos
PE20070333A1 (es) Composicion farmaceutica que comprende agomelatina para el tratamiento de transtornos del sueno en pacientes deprimidos
CL2009000803A1 (es) Uso de una variante de igf-1 pegilada para tratar, prevenir un trastorno neuromuscular; metodo para el tratamiento, prevencion y/o demora de un trastorno neuromuscular; composicion que comprende la variante de igf-1 modificada
CL2007002494A1 (es) Composicion farmaceutica que comprende una pirimidina trisustituida en combinacion con un compuesto con propiedades inhibitorias de pde5; y uso en el tratamiento de una enfermedad que involucre vasoconstriccion.
AR052830A1 (es) Regimen de cladribina para tratar esclerosis multiple
CL2009001841A1 (es) Uso de una composición de liberación sostenida de 4-aminopiridina para preparar un medicamento útil para tratar esclerosis multiple en un sujeto.
NI200900073A (es) Compuestos de carbamato para su uso en el tratamiento de la depresión.
AR072951A1 (es) Uso de dronedarona o una sal aceptable farmaceuticamente de esta, para la preparacion de un medicamento para regular el nivel de potasio en la sangre
CL2007002759A1 (es) Forma de dosificacion solida de rapida desintegracion liofilizada que comprende una cantidad eficaz de un antagonista del receptor de trombina; y uso para tratar a un paciente que esta en riesgo de contraer el sindrome coronario agudo.
SV2010003773A (es) 7-sulfanilmetil-, 7-sulfinilmetil- y 7-sulfonilmetilindoles sustituidos y el uso de los mismos
PE20211199A1 (es) Uso de reboxetina para el tratamiento de narcolepsia
AR098832A1 (es) Uso de laquinimod para retrasar la progresión de la enfermedad de huntington
HN2011000661A (es) Composicion farmaceutica para el uso en el tratamiento de infecciones de transmision sexual
ECSP066836A (es) Piperazinas derivadas de úrea para el tratamiento de la endometrosis

Legal Events

Date Code Title Description
FC Application refused